ArticleNPJ breast cancer2024
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program.
Open access · goldAbstract read
In one paragraph
Article in NPJ breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Review
- Palmitate promotes liver metastases by decreasing neutrophil antitumour behaviour.Nature metabolism · 2026Article
- Patient-derived resources for decoding and targeting brain metastases ecosystems.EMBO molecular medicine · 2026Review
- Palmitoylation-mediated regulation of KAT2A promotes lung metastasis in breast cancer.Nature cell biology · 2026Article
- Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevance.NPJ breast cancer · 2026Review
- Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programs.NPJ breast cancer · 2026Article
- Expression of antibody-drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue.Nature communications · 2025Article
- ctDNA detectability and representativeness in seven body liquids from patients with metastatic breast cancer.Nature communications · 2025Article
- Advancing HIV and Cancer Research: Implementing an AIDS and Cancer Specimen Resource in Latin America.Biopreservation and biobanking · 2025Article
- Enhancing translational research in metastatic cancer through an open science environment: the UPTIDER experience.NPJ precision oncology · 2025Article
- Hope for OTHERS (Our Tissue Helping Enhance Research & Science): research results from the University of Pittsburgh rapid autopsy program for breast cancer.Breast cancer research : BCR · 2025Article
- Article
- Organ-Specific Immune Setpoints Underlie Divergent Immune Profiles across Metastatic Sites in Breast Cancer.Cancer immunology research · 2024Article
- Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program.NPJ breast cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 9 institutions in 6 countries.
Tatjana Geukens *Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Maxim De Schepper *Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Wouter Van Den Bogaert *Department of Forensic Medicine, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-5803-3409
Karen Van BaelenLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-5700-3574
Marion MaetensLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Anirudh PabbaLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Amena MahdamiLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3226-6933
Sophia LeducLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Edoardo IsnaldiLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Ha-Linh NguyenLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-2538-7657
Imane BachirLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Maysam HajipirlooLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Gitte ZelsLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Josephine Van CauwenbergeLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-9802-186X
Kristien BorremansLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-7047-1543
Vincent VandecaveyeDepartment of Radiology, University Hospitals Leuven, Leuven, Belgium.
Birgit WeynandDepartment of Pathology, University Hospitals Leuven, Leuven, Belgium.
Peter VermeulenCentre for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.
Eleonora LeucciTRACE and Laboratory for RNA Cancer Biology, Department of Oncology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-2898-748X
Maria Francesca BaiettiTRACE and Laboratory for RNA Cancer Biology, Department of Oncology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-1495-226X
George SflomosISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-2972-0549
Laura BattistaISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-9370-6736
Cathrin BriskenISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-6857-3230
Patrick W B DerksenDepartment of Pathology, University Medical Center, Utrecht, The Netherlands.
Thijs KoormanDepartment of Pathology, University Medical Center, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-6064-3353
Daan VisserDepartment of Pathology, University Medical Center, Utrecht, The Netherlands.
Colinda L G J ScheeleLaboratory of Intravital Microscopy and Dynamics of Tumor Progression, Department of Oncology, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.ORCID http://orcid.org/0000-0001-8999-5451
Daniela S ThommenDivision of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Sigrid HatseLaboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
Sarah-Maria FendtLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0001-6018-9296
Evy VanderheydenLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium, and VIB Center for Cancer Biology, Leuven, Belgium.
Thomas Van BrusselLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium, and VIB Center for Cancer Biology, Leuven, Belgium.
Rogier SchepersLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium, and VIB Center for Cancer Biology, Leuven, Belgium.
Bram BoeckxLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium, and VIB Center for Cancer Biology, Leuven, Belgium.
Diether LambrechtsLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium, and VIB Center for Cancer Biology, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3429-302X
Giuseppe MaranoUnit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) "L. Sacco" & DSRC, LITA Vialba campus, Università degli Studi di Milano, Milan, Italy.
Elia BiganzoliUnit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) "L. Sacco" & DSRC, LITA Vialba campus, Università degli Studi di Milano, Milan, Italy.ORCID http://orcid.org/0000-0003-1202-5873
Ann SmeetsDepartment of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-5091-6602
Ines NevelsteenDepartment of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium.
Kevin PunieDepartment of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-1162-7963
Patrick NevenDepartment of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium.
Hans WildiersDepartment of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-8990-7837
François RichardLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0003-4353-3619
Giuseppe FlorisDepartment of Pathology, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0003-2391-5425
Christine DesmedtLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium. christine.desmedt@kuleuven.be.ORCID http://orcid.org/0000-0002-5223-5579
Breast Cancer Research Foundation · USKU Leuven · BEVIB-KU Leuven Center for Cancer Biology · BEUniversity Medical Center Utrecht · NLÉcole Polytechnique Fédérale de Lausanne · CHUniversity of Milan · ITInstitute of Cancer Research · GBThe Netherlands Cancer Institute · NLUniversity of Antwerp · BE
Funding
EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) ITN-2019-859860-CANCERPREVEuropean Cooperation in Science and Technology (COST) LOBSTERPOT CA19138Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 1297322NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 1802222NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 1S76522NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G0B6120N, G093821NKU Leuven (Katholieke Universiteit Leuven) C14/18/092 and C14/22/125KU Leuven (Katholieke Universiteit Leuven) C14/21/114
Abstract
Research on metastatic cancer has been hampered by limited sample availability. Here we present the breast cancer post-mortem tissue donation program UPTIDER and show how it enabled sampling of a median of 31 (range: 5-90) metastases and 5-8 liquids per patient from its first 20 patients. In a dedicated experiment, we show the mild impact of increasing time after death on RNA quality, transcriptional profiles and immunohistochemical staining in tumor tissue samples. We show that this impact can be counteracted by organ cooling. We successfully generated ex vivo models from tissue and liquid biopsies from distinct histological subtypes of breast cancer. We anticipate these and future findings of UPTIDER to elucidate mechanisms of disease progression and treatment resistance and to provide tools for the exploration of precision medicine strategies in the metastatic setting.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.